Dexmedetomidine: another arrow in the quiver to fight COVID-19 in intensive care units

Br J Anaesth. 2021 Jan;126(1):e35-e38. doi: 10.1016/j.bja.2020.10.010. Epub 2020 Oct 14.

Authors

Amit Jain¹, Massimo Lamperti², D John Doyle³

Affiliations

¹ Anesthesiology Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. Electronic address: amitvasujain@gmail.com.
² Anesthesiology Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
³ Anesthesiology Institute, Cleveland Clinic, Case Western Reserve University, Cleveland, OH, USA.

No abstract available

Keywords: COVID-19; ICU; NETosis; dexmedetomidine; inflammation; sedation.

Publication types

Letter
Comment

MeSH terms

COVID-19*
Dexmedetomidine*
Humans
Hypnotics and Sedatives
Intensive Care Units
Lidocaine
SARS-CoV-2

Substances

Hypnotics and Sedatives
Dexmedetomidine
Lidocaine